Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma
연구 개요
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
California
-
Bakersfield, California, 미국, 93309
- Research Site
-
Bakersfield, California, 미국
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
-
Burbank, California, 미국, 91505
- Research Site
-
Burbank, California, 미국
- Providence Saint Joseph Medical Center
-
Fountain Valley, California, 미국, 92708
- Research Site
-
Fountain Valley, California, 미국
- Compassionate Care Research Group, Inc.
-
Los Angeles, California, 미국, 90017
- Research Site
-
Los Angeles, California, 미국, 90095-1686
- Research Site
-
Los Angeles, California, 미국
- Los Angeles Hematology / Oncology Medical Group
-
Whittier, California, 미국, 90603
- Research Site
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Research Site
-
Aurora, Colorado, 미국
- University of Colorado
-
-
District of Columbia
-
Washington, District of Columbia, 미국, 20057
- Research Site
-
Washington, District of Columbia, 미국
- Lombardi Cancer Center, Pediatric Hematology Oncology
-
-
Florida
-
Fort Myers, Florida, 미국
- Florida Cancer Specialists
-
Fort Myers, Florida, 미국, 33905
- Research Site
-
Tampa, Florida, 미국, 33612
- Research Site
-
Tampa, Florida, 미국
- H. Lee Moffitt Cancer Center & Research Institute
-
West Palm Beach, Florida, 미국, 33401
- Research Site
-
West Palm Beach, Florida, 미국
- Florida Cancer Specialists
-
-
Illinois
-
Chicago, Illinois, 미국
- University of Chicago Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Research Site
-
Boston, Massachusetts, 미국
- Dana Farber Partners Cancer Care
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- Research Site
-
-
New Jersey
-
Hackensack, New Jersey, 미국, 07601
- Research Site
-
Hackensack, New Jersey, 미국
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
New York
-
New York, New York, 미국, 10021
- Research Site
-
New York, New York, 미국, 10065
- Research Site
-
New York, New York, 미국
- Memorial Sloan Kettering
-
New York, New York, 미국
- Weill Cornell Medical College
-
New York, New York, 미국
- Clinical Research Alliance
-
New York, New York, 미국
- Morton Coleman, MD
-
Stony Brook, New York, 미국, 11794
- Research Site
-
Stony Brook, New York, 미국
- Stony Brook University Medical Center
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- Research Site
-
Durham, North Carolina, 미국
- Durham Veterans Affairs Medical Center
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45242
- Research Site
-
Cincinnati, Ohio, 미국
- Sarah Cannon Research Institute
-
-
Oregon
-
Bend, Oregon, 미국, 97701
- Research Site
-
Bend, Oregon, 미국
- Bend Memorial Clinic
-
-
South Carolina
-
Charleston, South Carolina, 미국, 29424
- Research Site
-
Charleston, South Carolina, 미국
- Medical University of South Carolina, Hollings Cancer Center
-
Greenville, South Carolina, 미국, 29607
- Research Site
-
Greenville, South Carolina, 미국
- Greenville Health System
-
Greenville, South Carolina, 미국
- Saint Francis Hospital Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, 미국, 57105
- Research Site
-
Sioux Falls, South Dakota, 미국
- Avera Cancer Institute
-
-
Tennessee
-
Germantown, Tennessee, 미국, 38138
- Research Site
-
Memphis, Tennessee, 미국
- The West Clinic, PC
-
Nashville, Tennessee, 미국, 37203
- Research Site
-
Nashville, Tennessee, 미국, 37232
- Research Site
-
Nashville, Tennessee, 미국
- Vanderbilt University Medical Center
-
Nashville, Tennessee, 미국
- Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute
-
-
Utah
-
Salt Lake City, Utah, 미국, 84112
- Research Site
-
Salt Lake City, Utah, 미국
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, 미국, 98104
- Research Site
-
Seattle, Washington, 미국
- Swedish Cancer Institute
-
-
Wisconsin
-
Milwaukee, Wisconsin, 미국
- Aurora Health Care, Aurora Cancer Care
-
Wauwatosa, Wisconsin, 미국, 53226
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Newly diagnosed or relapsed multiple myeloma
- Measureable disease by serum M protein, or urine M protein, or serum free light chain (SFLC) and an abnormal serum kappa lambda ratio (for subjects without detectable serum or urine M-protein), or serum quantitative immunoglobulin A (glgA) (for immunoglobulin (Ig) A subjects whose disease can only be reliable measured by qlgA).
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2
- Left ventricular ejection fraction (LVEF) ≥ 40%
Key Exclusion Criteria:
- Waldenström macroglobulinemia
- For newly diagnosed multiple myeloma: multiple myeloma of IgM subtype
For relapsed disease:
- If treated with a lenalidomide and dexamethasone combination, progression during the first 3 months after initiating treatment.
- Any progression during treatment if the lenalidomide and dexamethasone regimen was the most recent line of therapy.
- Any prior treatment with carfilzomib
- POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
- Plasma cell leukemia (> 2.0 × 10^9/L circulating plasma cells by standard differential)
- Myelodysplastic syndrome
- Amyloidosis
- Prior treatment with carfilzomib or oprozomib
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: RRMM Dose-evaluation: Carfilzomib 56 mg/m²
Participants with relapsed or refractory multiple myeloma (RRMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
|
실험적: RRMM Dose-evaluation: Carfilzomib 70 mg/m²
Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
|
실험적: RRMM Dose-expansion: Carfilzomib 70 mg/m²
Participants with RRMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
|
실험적: NDMM Dose-evaluation: Carfilzomib 56/70 mg/m²
Participants with newly diagnosed multiple myeloma (NDMM) received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1 day 1, 56 mg/m² on cycle 1 days 8 and 15, and then 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
|
실험적: NDMM Dose-expansion: Carfilzomib 70 mg/m²
Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 70 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
|
실험적: NDMM Dose-expansion: Carfilzomib 56 mg/m²
Participants with NDMM received treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) for up to eighteen 28-day cycles, or until disease progression, patient withdrawal, stem cell transplant, or death. Participants received carfilzomib on days 1, 8, and 15 of each cycle. The dose was 20 mg/m² on cycle 1, day 1, and 56 mg/m² thereafter. Participants also received lenalidomide 25 mg once daily on days 1-21 and dexamethasone 40 mg (oral or IV) on days 1, 8, and 15 of each cycle, and on day 22 of cycles 1 to 8. |
Administered once weekly by 30-minute intravenous (IV) infusion on days 1, 8, and 15 of each 28-day cycle.
다른 이름들:
Administered orally once daily on days 1-21 of each 28-day cycle.
다른 이름들:
Administered by mouth or IV at 40 mg on days 1, 8, and 15 of each 28-day cycle and on day 22 of cycles 1 to 8.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Adverse Events (AEs)
기간: From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.
|
Safety and tolerability were evaluated according to the type, incidence, and severity of adverse events. An AE is defined as any untoward medical occurrence in a clinical trial subject. The event does not necessarily have a causal relationship with study treatment. A serious adverse event is defined as an AE that meets at least 1 of the following serious criteria:
The severity of each AE was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03 where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Death. |
From the first dose of any study drug up to 30 days after the last dose of any study drug; median (range) duration of treatment with carfilzomib was 32 (1.1, 76.7) weeks in RRMM participants and 26 (1.0, 94.4) weeks in NDMM participants.
|
|
Change From Baseline in Hemoglobin Levels
기간: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
|
|
Change From Baseline in Platelet Count
기간: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
|
|
Change From Baseline in Neutrophil Count
기간: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
|
|
Change From Baseline in Bilirubin
기간: Baseline and Cycle 2 day 1
|
Baseline and Cycle 2 day 1
|
|
|
Change From Baseline in Creatinine
기간: Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
Baseline and Cycle 1, days 8 and 15 and Cycle 2 days 1, 8, and 15
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
기간: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
|
|
Time to Maximum Plasma Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
기간: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
|
|
Area Under the Curve From Time Zero to Time of Last Quantifiable Concentration of Carfilzomib on Day 8 of Cycle 1 by Dose Group
기간: Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
Day 8 of Cycle 1 at predose, 15 minutes after the start of infusion, at the end of infusion, and 15 and 60 minutes after the end of infusion
|
|
|
Overall Response Rate (ORR)
기간: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
Response was determined by the investigator based on the International Myeloma Working Group Uniform Response Criteria (IMWG URC). ORR was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). Responses must have been confirmed in 2 consecutive assessments at any time prior to initiation of any new therapy. Disease assessments included serum protein electrophoresis (SPEP) with immunofixation, urine protein electrophoresis (UPEP; 24-hour assessment) with immunofixation, serum free light chain (SFLC), quantitative immunoglobulins, bone marrow aspirates to determine percent plasma cell involvement, and skeletal imaging for plasmacytoma evaluation. |
Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
|
Complete Response Rate (CRR)
기간: Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
Complete Response Rate (CRR) is defined as the percentage of participants who achieved a best overall response of either stringent complete response (sCR) or complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). sCR: As for CR, and absence of clonal plasma cells in bone marrow (BM) CR: Negative serum and urine immunofixation, disappearance of any soft tissue plasmacytomas, < 5% plasma cells in BM, and normal SFLC ratio in participants with measurable disease only by SFLC. |
Response assessments were performed on day 1 of each treatment cycle from cycle 2 and then every 8 weeks during follow-up until disease progression. Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
|
Progression-free Survival (PFS)
기간: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
PFS is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause. Disease progression was determined by the investigator according to IMWG-URC. Progressive Disease (PD): Increase of 25% from lowest value in serum M-component (absolute increase ≥ 0.5 g/dL), urine M-component (absolute increase ≥ 200 mg per 24 hours) and/or the difference between involved and uninvolved FLC levels (absolute increase >10 mg/dL) in patients without measurable serum and urine M-protein levels, and/or any new or increase in size of bone lesions or soft tissue plasmacytomas, or development of hypercalcemia. PFS was analyzed using Kaplan-Meier methods. Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after > 1 consecutively missed assessment visit, were lost to follow-up or withdrew consent were censored at the date of last disease assessment. |
From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
|
Duration of Response (DOR)
기간: From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
Duration of response (DOR) was calculated for participants who achieved a confirmed PR or better based on Investigator assessment and according to the IMWG URC.
Duration of overall response is defined as the time from first documentation of response to disease progression or death due to any cause.
DOR was analyzed using Kaplan-Meier methods.
Participants who were alive with no documented PD, started new anticancer therapy before documentation of PD or death, had death or PD immediately after > 1 consecutively missed disease assessment visit, were lost to follow-up, or withdrew consent were censored at the date of last disease assessment.
|
From first dose of study drug until the end of follow-up; Median time on follow-up was 10.6 months in RRMM participants and 6.9 months in NDMM participants.
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Amy Kimball, MD, Amgen
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CFZ013
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .